Zebra Capital Management LLC Catalyst Pharmaceuticals, Inc. Transaction History

Zebra Capital Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$6.23 - $8.57 $1,638 - $2,253	-263 Reduced 2.26%	11,382 $80,000
Q1 2022 May 16, 2022	SELL	$5.31 - $8.31 $31,052 - $48,596	-5,848 Reduced 33.43%	11,645 $97,000
Q4 2021 Feb 14, 2022	SELL	$5.21 - $7.45 $33,599 - $48,045	-6,449 Reduced 26.94%	17,493 $118,000
Q3 2021 Nov 15, 2021	SELL	$4.85 - $6.04 $112,287 - $139,838	-23,152 Reduced 49.16%	23,942 $127,000
Q2 2021 Aug 16, 2021	SELL	$4.29 - $6.05 $21,823 - $30,776	-5,087 Reduced 9.75%	47,094 $271,000
Q1 2021 May 17, 2021	BUY	$3.45 - $4.69 $180,024 - $244,728	52,181 New	52,181 $241,000
Q3 2020 Nov 16, 2020	SELL	$2.97 - $5.08 $132,652 - $226,893	-44,664 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$3.48 - $5.05 $3,514 - $5,100	-1,010 Reduced 2.21%	44,664 $206,000
Q1 2020 May 15, 2020	SELL	$2.61 - $5.21 $960 - $1,917	-368 Reduced 0.8%	45,674 $176,000
Q4 2019 Feb 14, 2020	BUY	$3.67 - $5.7 $168,974 - $262,439	46,042 New	46,042 $173,000

348

98.4M

13.4K

11.7K

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.54B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

Get notified when there are updates to the investment portfolio of Zebra Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Zebra Capital Management LLC with notifications on news.